Levi & Korsinsky, LLP announces that a OCGN class action lawsuit has been filed on behalf of investors who purchased Ocugen, Inc. (OCGN) securities between February 2, 2021 and June 10, 2021. For more on the OCGN Lawsuit please contact us today.
According to the Ocugen, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) the information submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an Emergency Use Authorization (“EUA”), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Ocugen’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Ocugen, Inc. you have until August 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.